Format

Send to

Choose Destination
J Cardiol Cases. 2018 Mar 19;17(6):204-207. doi: 10.1016/j.jccase.2018.02.003. eCollection 2018 Jun.

Multiple potency of ezetimibe in a patient with macroproteinuric chronic kidney disease and statin-intolerant dyslipidemia.

Author information

1
Department of Cardiovascular Medicine, Saga University, Saga, Japan.
2
Division of Nephrology, Department of Internal Medicine, Shinmatsudo Central General Hospital, Matsudo, Japan.
3
Department of Pathology, Saitama Medical Center, Dokkyo University School of Medicine, Koshigaya, Japan.

Abstract

Dyslipidemia is often complicated by chronic kidney disease (CKD). Lipid-lowering medications may be effective, in part, for inhibiting development and progression of CKD. Ezetimibe, a cholesterol absorption inhibitor, has pleiotropic actions, including anti-inflammatory and anti-oxidant effects, contributing to a decreased risk of cardiovascular diseases. A 40-year-old woman was admitted with dyslipidemia and macroproteinuria, whose samples of renal biopsy showed exudative lesions, but without glomerular basement membrane thickening or nodular lesions, in some glomeruli. Blood glycemic parameters were normal. After initiation of atorvastatin, she developed muscle pain and an increase in serum creatine kinase. Twelve months after switching to ezetimibe, serum levels of low-density lipoprotein cholesterol and triglyceride reduced from 170 mg/dL to 116 mg/dL and from 320 mg/dL to 160 mg/dL, respectively. Although serum creatinine levels remained unchanged after 12 months, urinary protein excretion and urinary liver-type fatty acid binding protein were reduced. Flow-mediated dilatation also increased from 4.9% to 5.5% after 12 months, associated with a slight decrease in mean intima-media thickness in the common carotid artery from 0.722 mm to 0.718 mm. These results suggest that ezetimibe protects against renal and vascular damage in patients with CKD and statin-intolerant dyslipidemia. <Learning objective: Little is known whether ezetimibe monotherapy is safe and effective for renal/vascular function in patients with chronic kidney disease (CKD). We report that ezetimibe monotherapy for 12 months improved lipid profiles in a patient with CKD and statin-intolerant dyslipidemia. Ezetimibe also reduced proteinuria and urinary liver-type fatty acid binding protein levels, improved endothelial function, and decreased carotid atherosclerosis. These findings suggest that ezetimibe monotherapy may have beneficial multipotent effects on renal/vascular function.>.

KEYWORDS:

Carotid atherosclerosis; Chronic kidney disease; Endothelial function; Ezetimibe; Statin-intolerant dyslipidemia

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center